# Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Page: https://stenobird.com/podcast/biospace-6696251/moderna-s-fda-adcomm-ipo-mania-biopharma-layoffs-more
Text version: https://stenobird.com/podcast/biospace-6696251/moderna-s-fda-adcomm-ipo-mania-biopharma-layoffs-more.md
Podcast: [BioSpace](https://stenobird.com/podcast/biospace-6696251)
Published: 2026-06-17T07:00:00+00:00
Episode link: https://api.riverside.com/hosting-analytics/media/e7bb922ecd74ca99f6e7a22a6540717a4e3f8f3c899bcc523104932b683d3fcf/eyJlcGlzb2RlSWQiOiJmYTJhN2M5Ny02MTMxLTRiNmMtYWE5Yy04YmU3ZjkwNjhkZjQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEzMTk5ZDMyZDIwNmMwZDI2NThjMjUwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTE2X18yMC00NS0zOS5tcDMifQ==.mp3
Audio file: https://api.riverside.com/hosting-analytics/media/e7bb922ecd74ca99f6e7a22a6540717a4e3f8f3c899bcc523104932b683d3fcf/eyJlcGlzb2RlSWQiOiJmYTJhN2M5Ny02MTMxLTRiNmMtYWE5Yy04YmU3ZjkwNjhkZjQiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEzMTk5ZDMyZDIwNmMwZDI2NThjMjUwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTE2X18yMC00NS0zOS5tcDMifQ==.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/moderna-s-fda-adcomm-ipo-mania-biopharma-layoffs-more
Duration seconds: 1533

## Resource

Moderna’s mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment , though the agency did flag certain data gaps for advisors to review. Biotech IPOs are off the charts—literally. This past month has seen not one but two record-setting public debuts. First there was Kailera Therapeutics , which hit the market with $625 million in April, outpacing Moderna’s 2018 IPO of $600 million. And now we have Parabilis Medicines , which last week dethroned Kailera as the largest biotech IPO of all time, with $670 million. Meanwhile, the number of employees laid off spiked by almost 50% year-over-year in May, though that jump is mostly due to significant cuts at Takeda and BioNTech. Genentech also made a big change last week. Eli Lilly continued its dealmaking spree with AlzeCure, striking a licensing agreement worth up to $1 billion centering on a small-molecule asset for Alzheimer’s disease. But the bigger Lilly news in the past week was clinical results that show promise for the pharma’s $2.3 billion acquisition of Ajax Therapeutics in April. Earlier this month, the FDA held a public session to glean feedback regarding the Commissioner’s National Priority Voucher program, in which several groups called for a temporary pause to the pilot, citing concerns about transparency and political involvement. While the future of that program hangs in the balance, two voucher holders got updates this week. First, Sanofi’s diabetes drug Tzield was greenlit for older kids and teenagers, though it’s unclear whether…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/moderna-s-fda-adcomm-ipo-mania-biopharma-layoffs-more/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/biospace-6696251/moderna-s-fda-adcomm-ipo-mania-biopharma-layoffs-more.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.